This week, CancerNetwork spoke with Matthew Matasar, MD, a lymphoma specialist and chief of the Medical Oncology Service at Memorial Sloan Kettering Cancer Center Bergen, about research from the December issue of ONCOLOGY titled, “Real-World Assessment of Patient Care and Practice Efficiency With the Introduction of Subcutaneous Rituximab.”

The retrospective, observational analysis examined patient care delivery and practice efficiency changes using real-world data. Patients with diffuse large B-cell lymphoma, follicular lymphoma, or chronic lymphocytic leukemia who received a rituximab-containing regimen were eligible for the study.

Matasar touched on subcutaneous rituximab, the role it can play in treatment, the time savings associated with its use, and more.

Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify or anywhere podcasts are available.